Replies to post #89118 on Biotech Values

[steveporsche]

Nope, you are double counting some of those shares:

January 15, 2010 4:27 PM EST

In a 13G filing after the close on Dendreon (Nasdaq: DNDN), Steven Cohen's S.A.C. Capital disclosed a 5.5%, or 7,282,030 share, stake in the biotech company. The firm held just 150,000 shares of DNDN at the quarter ended September 30, 2009. A 13G indicates a passive investment above 5%.



Dendreon is expected to be given approval for prostate cancer treatment Provenge which is expected to be blockbuster therapy for this indication and maybe others.

http://www.streetinsider.com/13Gs/Cohens+S.A.C.+Capital+Discloses+5.5%+Stake+In+Dendreon+(DNDN)/5252197.html